% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Cooley:300255,
      author       = {V. Cooley$^*$ and R. T. Fortner$^*$ and T. Mukama$^*$ and
                      S. Naudin and V. Pala and L. Dossus and I. T. Gram and K. S.
                      Olsen and M.-J. Sánchez and P. Israelsson and N. Allen and
                      H. Langseth and R. Kaaks$^*$},
      title        = {{P}rospective evaluation of 92 protein biomarkers for early
                      detection of endometrial cancer.},
      journal      = {International journal of cancer},
      volume       = {157},
      number       = {3},
      issn         = {0020-7136},
      address      = {Bognor Regis},
      publisher    = {Wiley-Liss},
      reportid     = {DKFZ-2025-00716},
      pages        = {480-489},
      year         = {2025},
      note         = {#EA:C020#LA:C020# / 2025 Aug 1;157(3):480-489},
      abstract     = {The human epididymis protein 4 (HE4) remains the best
                      available endometrial cancer (EC) biomarker; however, its
                      discrimination between cases and cancer-free individuals is
                      limited and might be improved when combined with other
                      protein markers. We evaluated the discrimination capacity of
                      92 proteins as potential early detection biomarkers for EC
                      in nested case-control studies in the European Prospective
                      Investigation into Cancer and Nutrition (EPIC) (63 cases,
                      123 controls) and Janus (75 cases, 146 controls) cohorts,
                      evaluating blood samples taken ≤2 years prior to
                      diagnosis. Proteins were measured with the Olink Target 96
                      Oncology II panel assays. Areas under the receiver operating
                      characteristic curves (AUCs) were calculated using logistic
                      regression. The discrimination between cases and controls of
                      top-performing proteins was modest (EPIC: HE4, CA125, CAIX,
                      and S100A4; Janus: HE4, CA125, FURIN, CXCL13, and IL6; AUC
                      range: 0.65 [S100A4], 0.76 [HE4, EPIC] within 0 to <12
                      months of blood collection) and decreased as the time
                      between blood draw and cancer diagnosis increased (12-24
                      months AUC range: 0.49 [S100A4], 0.69 [CA125, Janus]). The
                      combination of these other markers with HE4 did not improve
                      discrimination. HE4 and other candidate proteins had limited
                      discrimination between EC cases and controls and hence do
                      not appear to be useful for early detection of this disease
                      in women at average population risk.},
      keywords     = {biomarkers (Other) / early detection (Other) / endometrial
                      cancer (Other)},
      cin          = {C020},
      ddc          = {610},
      cid          = {I:(DE-He78)C020-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40177982},
      doi          = {DOI:10.1002/ijc.35428},
      url          = {https://inrepo02.dkfz.de/record/300255},
}